Skip to main content
Premium Trial:

Request an Annual Quote

Xenomics Changes Name to TrovaGene

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – San Diego-based Xenomics has changed its name to TrovaGene and its ticker symbol to TROV, effective yesterday.

The firm is developing molecular diagnostics based on its transrenal nucleic acid technology. TrovaGene said that it has leased a 5000-square-foot facility in the Sorrento Valley area of San Diego and is in the process of completing all the necessary laboratory validations. The firm added that it plans to expand its scientific team as it works toward becoming a fully integrated diagnostic business by the end of the second quarter of this year.

Among the products TrovaGene has in development are a KRAS assay and an assay for human papillomavirus genotypes.

TrovaGene's shares currently trade at $.59 on the Pink Sheets.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.